Interestingly, both the side-effects and reduced anti-tumor effects of NF-κB inhibitors in vivo might be due to the excessive sensitivity of NF-κB-inactivated cells to TNF-induced activation of JNK signaling [19]. The gene discussed is NFKB1; the disease is neoplasm.